Lixte Biotechnology Holdings Inc Stock

$3.71

12.42% yesterday

Nasdaq, Jul 15, 10:19 pm CET

ISIN

US5393192027

Symbol

LIXT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Lixte Biotechnology Holdings Inc Stock price

$3.71

+2.81 312.22% 5Y

Nasdaq, Closing price Tue, Jul 15 2025

+0.41 12.42%

ISIN

US5393192027

Symbol

LIXT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$10.7m

Enterprise Value

$9.4m

Net debt

positive

Cash

$1.4m

Shares outstanding

2.7m

Valuation (TTM | estimate)

P/E

negative | -

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

9.3

Financial Health

Equity Ratio

72.2%

Return on Equity

-433.5%

ROCE

-288.1%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | -

EBITDA

- | -

EBIT

$-3.3m | -

Net Income

$-3.3m | -

Free Cash Flow

$-2.9m

EPS

$-1.3

FCF per Share

$-1.1

Short interest

0.2%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Get Started for Free Today

Lixte Biotechnology Holdings Inc Stock Analysis

Unlock Scores for Free

??

Financial data from Lixte Biotechnology Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	3.06 3.06	10% 10% -
- Research and Development Expense	0.70 0.70	16% 16% -
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-3.31 -3.31	29% 29% -
Net Profit	-3.32 -3.32	29% 29% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Lixte Biotechnology Holdings Inc Stock News

Neutral

GlobeNewsWire

●

7 days ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

New York, NY, July 09, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent.

Neutral

GlobeNewsWire

●

7 days ago

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Article Indicates that Inhibition of PP2A Enhances Immunotherapy Response with LIXTE's Proprietary Compound LB100

Neutral

GlobeNewsWire

●

8 days ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

New York, NY, July 08, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $5.0 million private placement for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent.

More Lixte Biotechnology Holdings Inc News

Company Profile

Lixte Biotechnology Holdings, Inc. engages in the development of drugs for cancer treatment. The firm uses biomarker technology to identify enzyme targets associated with serious common diseases and designs novel compounds to attack those targets. Its product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in East Setauket, NY.

Head office	United States
CEO	Bastiaan Baan
Employees	4
Founded	2005
Website	lixte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now